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Abstract
Background: Despite a huge well-documented literature on cognitive deficits in schizophrenia,
little is known about the own perception of patients regarding their cognitive functioning. The
purpose of our study was to create a scale to collect subjective cognitive complaints of patients
suffering from schizophrenia with Tunisian Arabic dialect as mother tongue and to proceed to a
validation study of this scale.
Methods:  The authors constructed the Self-Assessment Scale of Cognitive Complaints in
Schizophrenia (SASCCS) based on a questionnaire covering five cognitive domains which are the
most frequently reported in the literature to be impaired in schizophrenia. The scale consisted of
21 likert-type questions dealing with memory, attention, executive functions, language and praxia.
In a second time, the authors proceeded to the study of psychometric qualities of the scale among
105 patients suffering from schizophrenia spectrum disorders (based on DSM- IV criteria). Patients
were evaluated using the Positive and Negative Syndrome Scale (PANSS), the Global Assessment
Functioning Scale (GAF scale) and the Calgary Depression Scale (CDS).
Results: The scale's reliability was proven to be good through Cronbach alpha coefficient equal to
0.85 and showing its good internal consistency. The intra-class correlation coefficient at 11 weeks
was equal to 0.77 suggesting a good stability over time. Principal component analysis with Oblimin
rotation was performed and yielded to six factors accounting for 58.28% of the total variance of
the scale.
Conclusion: Given the good psychometric properties that have been revealed in this study, the
SASCCS seems to be reliable to measure schizophrenic patients' perception of their own cognitive
impairment. This kind of evaluation can't substitute for objective measures of cognitive
performances in schizophrenia. The purpose of such an evaluation is to permit to the patient to
express his own well-being and satisfaction of quality of life.
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Background
It is now well proven that schizophrenia is associated with
multiple cognitive deficits [1-3] which can be profound
and devastating [4]. Patients with chronic schizophrenia
demonstrate impairments that range between one and a
half to two standard deviations below healthy controls on
several key dimensions of cognition [5], especially verbal
memory, working memory, motor speed, attention, exec-
utive functions and verbal fluency [6].
These deficits are thought to be a core feature of schizo-
phrenia and not simply the result of the symptoms or the
current treatments of the illness [7,8]. Moreover, they
seem to have an impact on functional outcome [9] as they
are correlated with poor functional abilities including
skills acquisition, problem solving, and community living
[10-12]. Furthermore, neurocognitive deficits are believed
to be the single strongest correlate of real-world function-
ing [13].
The number of publications on cognitive deficits in schiz-
ophrenia has grown vastly over the past two decades. At
the same time, an increasing number of sophisticated lab-
oratory tasks has been developed for a better assessment
of cognition [14]. However, little is known about how
patients suffering from schizophrenia perceive their own
cognition. Are they aware of their eventual cognitive
impairments? Do they realize that their social functioning
is highly influenced by these deteriorations? Do they com-
plain about their memory problems to their doctor and
do they demand specific treatments for them?
Traditionally, the study of subjective symptoms of schizo-
phrenic patients has been limited to delusions and hallu-
cinations [15]. Nowadays, abnormal subjective
experiences concerning fields other than delusions and
hallucinations are becoming more investigated since they
are believed to be important in understanding and treat-
ing schizophrenia [16,17]. From a historical point of
view, the first author who described a patient's subjective
experiences in schizophrenia was Huber [18,19]. This
German author introduced the term of "basic symptoms"
to designate the first symptoms of schizophrenia that con-
stitute the basis on which the others symptoms develop.
These symptoms do not include behavioural abnormali-
ties or verbal impairments that can be assessed objectively
by clinicians. In fact, they are only reported by patients
that describe them as subjective experiences of deficits
including loss of energy, motor dysfunctions, abnormal
corporeal sensations, altered cognitive processes, difficul-
ties to feel emotions and vulnerability to stress [20]. The
basic symptoms were targeted by a multitude of scales
comprising the Bonn Scale [21], the Frankfurt Complaint
Scale [22], the Subjective Experience of Deficit Scale [23],
the Interview on Subjective Experience [16], the Subjec-
tive Deficit Syndrome Scale [24] and the Ependorff Inven-
tory of Schizophrenia [25]. What is significant is that these
scales dealt with different aspects of subjective experiences
in schizophrenia including cognitive dysfunctions but
didn't focus specifically on the latter. Only one scale, the
SSTICS or Subjective Scale To Investigate Cognition in
Schizophrenia [14], assessed specifically the cognitive
subjective symptoms in schizophrenia. The psychometric
properties of this scale were evaluated within a popula-
tion of 114 French speaking schizophrenic patients. Vali-
dation study of the SSTICS was shown to be successful
proving that cognitive complaints in schizophrenia can be
reliably assessed.
To our knowledge, no similar instrument has been pub-
lished and validated in the Arabic language. Conse-
quently, the purpose of our study was to create a scale to
collect subjective cognitive complaints of patients suffer-
ing from schizophrenia whose mother tongue is Tunisian
Arabic.
Methods
Description of the scale
The authors constructed the Self-Assessment Scale of Cog-
nitive Complaints in Schizophrenia (SASCCS) based on a
questionnaire covering five cognitive domains which are
the most frequently reported in the literature to be
impaired in schizophrenia [6,26]. The scale consisted of
21 questions dealing with memory, attention, executive
functions, language and praxia. Memory was evaluated
through its components: working memory (item 1&2),
episodic memory (item 3 though 9) and semantic mem-
ory (item 10&11). Attention was investigated through its
components: distractibility (item 12), alertness (item13),
selective attention (item14), divided attention (item15)
and sustained attention (item16). Executive functions
were explored through their components: planning
(item17), organisation (item18) and flexibility (item19).
Finally, language was examined through item 20 and
praxia through item 21. The scale was made to be as clear,
simple and easy to use by patients suffering from schizo-
phrenia. It was written in Tunisian Arabic dialect. 'See
additional file 1: Tunisian version of the SASCCS'. 'See
additional file 2: English version of the SASCSS'.
Pre-test of experimental version
The questionnaire was first administered to a reduced
sample of 38 patients (35 men, 3 women) meeting the
DSM-IV diagnostic criteria for schizophrenia (n = 35) or
schizoaffective disorder (n = 3) [27]. The aim of this pre-
liminary work was to collect comments from both
patients and investigators in order to better formulate the
items and furthermore, to add examples to the questions
that closely suit the patient's daily life. Mean age of the
patients was 34 ± 8.9 years and time elapsed since onsetBMC Psychiatry 2009, 9:66 http://www.biomedcentral.com/1471-244X/9/66
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of the disease was 10.3 years (SD = 6.89). 'See additional
file 3: Table S1: demographic characteristics and psychia-
try history of pre-test sample'.
Mean total score of the PANSS was 61 ± 16 [28].
Accordingly to this purpose, item 8 was modified in a way
to provide examples corresponding to both men and
women in their daily activities. The wording of items 10,
14 and 15 was reviewed in a way to be clarified. This pre-
test also served to harmonize the modalities of the scale's
administration and the instructions given each time to the
patients.
Administration procedure
The SASCCS is a self-rated questionnaire administered
during a structured interview in which the investigator
explains to the patient the way he should answer to the 21
Likert-type questions of the scale. The patient is asked to
read each of the items in which problems of memory or
concentration of daily life are presented and may have
been experienced by him self. He is then asked to estimate
the frequency of occurrence of such situations in his own
life. For that purpose, he must circle the number that best
corresponds to his experienced life. (4-very often; 3-often;
2-sometimes; 1-rarely; 0-never). The SASCCS total score is
calculated by adding each item score together. The more
the patient complained about cognitive impairments, the
higher was the scale's total score.
The approximate time to completion was 15 minutes on
average. The questionnaire was administered at the outpa-
tient clinic. The same trained psychiatrist proceeded to the
administration of the scale among all participants. The
investigator should remain on site until the patient is
done with the questionnaire. He could provide explana-
tions to some questions or even examples to clarify the
meaning of items especially item 13, 15, 18 and 19. 'See
additional file 4: examples for items 13, 15, 18 and 19 of
the SASCCS'.
Characteristics of the population
The final version of the scale was then administered to
105 outpatients who met the DSM IV criteria for schizo-
phrenia (undifferentiated subtype, n = 47; paranoid sub-
type, n = 39; hebephrenic subtype, n = 6; residual subtype,
n = 3) or schizoaffective disorder (bipolar subtype, n = 8;
depressive subtype, n = 2). Patients were recruited from
three different outpatient clinics based in the Razi Hospi-
tal (La Manouba, Tunisia). They were carefully screened to
rule out an additional Axis I diagnosis or any disorder that
might alter brain functioning. They had to meet the fol-
lowing requirements:
(1) have a minimum educational level of 5 years,
(2) no evidence of mental retardation,
(3) being at the time of testing under unchanged medica-
tion dosage for the last 4 weeks.
(4) never undergone electroconvulsive therapy,
(5) no evidence of organic brain pathology including cer-
ebral tumor, epilepsy, systemic disease, history of cranial
trauma, brain surgery
(6) no history of substance abuse or dependence, and
consumption of psychoactive.
Table 1 shows sociodemographic sample characteristics
and its psychiatric history.
Psychopathological assessment
Psychopathological symptoms were evaluated using the
PANSS [29], the Calgary depression scale (CDS) [30] and
the Global Assessment Functioning scale (GAF scale) [27].
PANSS, CDS and EGF were administered by the same
trained psychiatrist for all participants. Mean scores on
these clinical scales were as follows: 52.84 (SD = 9.64) for
the PANSS total score, 1.35 [min = 0; max = 5] for the CDS
and 62.58 (SD = 13.88) for the GAF scale. Mean scores for
the PANSS subscales were as follows: 10.05 (SD = 2.5) for
the positive symptoms, 16.32 (SD = 4.49) for the negative
symptoms and 26.4 (SD = 5) for general psychopathol-
ogy. Mean score for the item G12 of the PANSS assessing
insight was 2.32 (SD = 1.15).
Using the 5-factor model of the PANSS as identified by
Lindenmayer et al. [31], we calculated the cognitive factor
and the depression factor which had respectively a score
of 10.14 (SD = 2.49) and 5.93 (SD = 1.99).
Statistical analysis
We conducted an exploratory principal component anal-
ysis (PCA) on the correlation matrix of the 21 items of the
SASCCS. Several guidelines were used to select the
number of factors: the Kaiser criteria and the interpretabil-
ity of the factors. Oblimin rotation was then performed.
Construct validity and reliability were evaluated by calcu-
lating Cronbach's alpha coefficient and the average of cor-
relations between each item and the total score.
Correlation analyses were performed using the Pearson
coefficient when data had normal distribution; elsewhere,
Spearman rank correlation was calculated.
Statistical significance level was set at p = 0.01 (two-
tailed).BMC Psychiatry 2009, 9:66 http://www.biomedcentral.com/1471-244X/9/66
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Statistical analyses were performed using SPSS software in
his 12th version.
Ethics and Consent
This research has been undergone in a psychiatric univer-
sity department in RAZI hospital. It has been approved by
the local ethic committee. Patients have signed a written
and informed consent.
Results
The SASCCS global score mean was 24.98 (SD = 14.83;
min = 0, max = 109; median = 24).
Reliability
Internal consistency
It was evaluated by calculating Cronbach's alpha coeffi-
cient [32] which was equal to 0.85 proving a good internal
consistency of the scale but furthermore, a satisfactory
reliability of its measure.
Test-retest reliability
Its was assessed within a subgroup of 39 patients exam-
ined by the same investigator at a mean interval of 80 days
(SD = 33). Intra-class correlation coefficient was equal to
0.77 (p = 0.00) suggesting a good stability over time.
Validity of internal structure
We carried out a factor analysis using principal compo-
nent analysis as the extraction method. The decision-mak-
ing for factor extraction was based on Kaiser criteria [33].
According to these criteria, the factors extracted should
have an eigenvalue greater than 1, provided that the total
variance explained exceeded 50%. PCA with Oblimin
rotation yielded six factors with 58.2% explained variance
(Table 2). The eigenvalues of the first two factors were
5.57 and 1.61, respectively, and the corresponding vari-
ances were 26.55% and 7.68%.
In order to evaluate cognition as conceptualized by sub-
jectivity, PCA with Oblimin rotation method [34] was
performed to see whether latent variables would emerge
and lead to a cognitive model different from the initial
theoretical one that have been the basis of our scale. After
carrying out an Oblimin Rotation, the items with a load-
ing higher then 0.50 were retained to be part of the sub-
jective cognitive factors (Table 3).
Correlations between psychopathological assessment and 
scale's scores
We examined whether correlations existed between scores
derived from the scale and positive, negative and disor-
Table 1: Demographic sample characteristics and psychiatric history
Variable
Age (years; mean, SD) 34 7
Gender (n)
Male 86 81.9%
Female 19 18.1%
Years of education (mean,SD)
9.7 3.1
Marital status (n)
Single 91 86.7%
Married 10 9.5%
Divorced 4 3.8%
Occupation (n)
Unemployed 60 57.2%
Working 40 38.1%
Studying 3 2.9%
Retired 2 1.9%
Duration of illness (years; mean, SD) 10.17 6.01
Number of hospitalisations (mean, min-max) 3 [0-22]
Total period of hospital stay (weeks; mean, min-max) 10.38 [0-60]
Neuroleptics (n)
Neuroleptics (n)
First generation
76 72.4%
Second generation 29 27.6%
Chlorpromazine equivalent of antipsychotic dosage (mean, SD) 482.5 322
Table 2: Principal component analysis: Total variance explained
Factor % of variance Cumulative %
1 26.55 26.55
2 7.68 34.24
3 6.77 41.01
4 6.55 47.56
5 5.65 53.22
6 5.06 58.28BMC Psychiatry 2009, 9:66 http://www.biomedcentral.com/1471-244X/9/66
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ganisation factors derived from the factorial analyses stud-
ies of the PANSS [35]. We also considered the item G 12
assessing insight as well as the Calgary Depression Scale
total score.
The SASCCS total score wasn't correlated to any of the
PANSS. A weak negative correlation between the SASCCS
total score and PANSS insight score was found (r = -.21)
but didn't reach the statistical significance (p = .03). Cal-
gary score was correlated with the SASCCS total score (r =
.33; p = .001).
The cognitive factor of the 5-factor model of the PANSS
wasn't correlated to the SASCCS total score or sub-scores.
The depression factor was correlated to the SASCCS total
score (r = .20) although this correlation didn't reach the
statistical significance (p = .03).
Discussion
The aim of this study was to construct and to validate a
scale to measure the subjectivity of patients with schizo-
phrenia regarding their cognition. The SASCCS, which
was easy to administer in less than 15 minutes, had good
reliability and stability over time. No cut-off has been
determined for this scale. In fact, the SASCCS total score is
used to estimate a patient's level of complaining.
The composition of subjective cognitive domains as
derived from factor analysis was slightly different from
that of the initial theoretical model which has been the
basis of the scale's construction. Actually, the scale's items
have been distributed after PCA differently from the orig-
inal structure of the scale leading to a neo-construct of the
instrument. These differences were not surprising since
the questionnaire was based on the neuropsychological
theoretical conception of cognition whereas factor analy-
sis of the scale reflected the patient's own perception of his
cognition. Stip et al., using the Subjective Scale To Investi-
gate Cognition in Schizophrenia (SSTICS), have also
found a difference between the distribution of the items
in the initial model and in the neo-construct of their scale
[14]. It could be that the selected items did not exactly
measure what they were supposed to. Also, their specifi-
city might be imperfect as it refers to several overlapping
dimensions.
These findings point to the complex representation of
schizophrenic patients of their own cognition. And even
though the latter does not correspond to the theoretical
construct of cognition, the scale remains reliable because
of both its good internal consistency and stability over
time.
During this study, no other instrument evaluating cogni-
tive functions was administered simultaneously to our
population. Therefore, convergent validity was unneces-
sary. However, when reviewing the literature, no positive
correlation was found between objective and subjective
scores of cognition. Using the SSTICS, Prouteau et al.
found that cognitive nature of subjective complaints did
not strictly match with that of impaired objective per-
formances [36]. Chan et al. assessed prospective memory
in patients with schizophrenia and did not find a correla-
tion between objective performances and subjective meas-
ures of this cognitive function [37].
These results suggest that subjective evaluation of cogni-
tion could be an independent dimension from its objec-
tive assessment in patients with schizophrenia.
In fact, in our study, no correlation has been found
between the SASCCS scores and the PANSS cognitive fac-
tor which could also point to the fact that self-assessment
of cognition is a totally independent aspect from clinical
evaluation of the cognitive functions.
The correlation of insight with subjective perception of
cognition in schizophrenia is an aspect that deserves to be
considered and analyzed.
In fact, awareness of one's own cognitive deficits could be
highly influenced by consciousness of one's whole condi-
tion as a mentally ill person. Schizophrenia is generally
accompanied by a lack of insight meaning an impaired
awareness of one's psychiatric condition and life situation
[38]. Therefore, low scoring at the SASCCS could be due
to a lack of insight.
In our study, a weak negative correlation between PANSS
insight score and SASCCS score has been found (r = -.21,
p = .03) but didn't reach the significance level set at 0.01.
However, it should be noticed that our study included a
majority of subjects scoring no more than 4 on the PANSS
insight item. Only one patient had a score of 5.
Since insight could influence one's subjective perception
of cognition, it is recommended to evaluate patient's
insight while using the SASCCS.
Table 3: Subjective cognitive domains of complaints
Subjective Factors Items Subjective domains
1 5, 12, 16, 20, 21 Distractibility
2 8, 9, 15, 18 Daily life
3 10, 11 Semantic memory
4 4, 6, 7 Disorder consciousness
5 1, 2 Working memory
6 3, 14, 17, 19 Executive skillsBMC Psychiatry 2009, 9:66 http://www.biomedcentral.com/1471-244X/9/66
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Another important factor to be considered is depression
since a depressive state could be accompanied by cogni-
tive disturbances in several domains such memory and
attention [39,40].
In our study, there was a positive correlation between SAS-
CCS total score and CDS score meaning that the more
depressive symptomatology is severe, the more the patient
reports cognitive troubles. Although it was not statistically
significant, we also did find a correlation between SAS-
CCS total score and the depression score of the 5-factor
model of the PANSS suggesting the influence that could
exert depression on self assessment of cognition by
emphasizing cognitive complaints when being more
depressed.
Lecardeur et al. found in their study using the SSTICS a
correlation between the scale total score and the PANSS
depression score. It could be suggested that subjective
complaints of cognitive deficits may influence a patient's
objective depressive state as rated by the clinician [41].
Considering the influence of depressive traits on subjec-
tive perception toward cognition, we recommend measur-
ing the patient's mood state when using the SASCCS.
Conclusion
We present here a self-assessment scale to evaluate cogni-
tive deficits as perceived by patients suffering from schiz-
ophrenia in domains of memory, attention and executive
functions. Given the good psychometric properties that
have been revealed in this study, the SASCCS seems to be
reliable to measure schizophrenic patients' perception of
their own cognitive impairment. This kind of evaluation
can not replace objective measures of cognitive perform-
ances in schizophrenia. Actually, the purpose of such an
evaluation is to allow the patient to express his own well-
being and satisfaction of quality of life. Furthermore, sub-
jective evaluation of cognitive functions could provide a
more complete picture of the cognitive profile of an indi-
vidual. Therefore, better therapeutic targets could be
adapted to his condition during cognitive rehabilitation
programs.
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